Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy
Cancer patients receiving non-endocrine therapies are at risk of hepatitis B virus (HBV) reactivation (HBVr). Guidelines recommend HBV screening prior to treatment. The Ottawa Hospital Cancer Center implemented a screening pilot for all patients receiving FOLFOX-based regimens between January and Ap...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/20 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588689895587840 |
|---|---|
| author | Jennifer Leigh Ranjeeta Mallick Stephanie Brule Lisa Rambout Jennifer Newton Dominick Bossé Curtis Cooper Joanna Gotfrit |
| author_facet | Jennifer Leigh Ranjeeta Mallick Stephanie Brule Lisa Rambout Jennifer Newton Dominick Bossé Curtis Cooper Joanna Gotfrit |
| author_sort | Jennifer Leigh |
| collection | DOAJ |
| description | Cancer patients receiving non-endocrine therapies are at risk of hepatitis B virus (HBV) reactivation (HBVr). Guidelines recommend HBV screening prior to treatment. The Ottawa Hospital Cancer Center implemented a screening pilot for all patients receiving FOLFOX-based regimens between January and April 2023. We assessed the pilot from a quality improvement perspective. Charts were retrospectively reviewed, and patient and disease characteristics were collected. The primary endpoint was to identify the proportion of patients who underwent HBV screening prior to treatment start. Univariate analyses assessed the association between baseline characteristics and failure to screen. Quality metrics were also reviewed. There were 32/42 patients (76.2%) who completed screening, and 5 (11.9%) had a positive screen. The majority of eligible patients (59.5%) completed screening prior to the first treatment as intended. Four of five patients who tested positive were referred to Infectious Diseases. Of those, one received antivirals for chronic HBV. There were no treatment delays due to pending screening and no HBV reactivation. Receipt of prior systemic therapy was significantly associated with failure to screen (55 vs. 95%, OR 17.1 (95% CI 1.92–153), <i>p</i> = 0.011). The results of this pilot highlight the importance of building HBV screening into standardized treatment plans and engaging all team members to ensure high levels of screening. Prior systemic therapy receipt was associated with failure to screen, and thus, programs should include education on the necessity of screening as recommended by medical guidelines. |
| format | Article |
| id | doaj-art-3c9b4bf6442941a0924017244175dc10 |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-3c9b4bf6442941a0924017244175dc102025-01-24T13:28:23ZengMDPI AGCurrent Oncology1198-00521718-77292024-12-013212010.3390/curroncol32010020Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer TherapyJennifer Leigh0Ranjeeta Mallick1Stephanie Brule2Lisa Rambout3Jennifer Newton4Dominick Bossé5Curtis Cooper6Joanna Gotfrit7Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaOttawa Hospital Research Institute, Ottawa, ON K1H 8L6, CanadaDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaThe Ottawa Hospital Pharmacy Department, Ottawa, ON K1H 8L6, CanadaThe Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaDivision of Infectious Diseases, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1Y 4E9, CanadaDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaCancer patients receiving non-endocrine therapies are at risk of hepatitis B virus (HBV) reactivation (HBVr). Guidelines recommend HBV screening prior to treatment. The Ottawa Hospital Cancer Center implemented a screening pilot for all patients receiving FOLFOX-based regimens between January and April 2023. We assessed the pilot from a quality improvement perspective. Charts were retrospectively reviewed, and patient and disease characteristics were collected. The primary endpoint was to identify the proportion of patients who underwent HBV screening prior to treatment start. Univariate analyses assessed the association between baseline characteristics and failure to screen. Quality metrics were also reviewed. There were 32/42 patients (76.2%) who completed screening, and 5 (11.9%) had a positive screen. The majority of eligible patients (59.5%) completed screening prior to the first treatment as intended. Four of five patients who tested positive were referred to Infectious Diseases. Of those, one received antivirals for chronic HBV. There were no treatment delays due to pending screening and no HBV reactivation. Receipt of prior systemic therapy was significantly associated with failure to screen (55 vs. 95%, OR 17.1 (95% CI 1.92–153), <i>p</i> = 0.011). The results of this pilot highlight the importance of building HBV screening into standardized treatment plans and engaging all team members to ensure high levels of screening. Prior systemic therapy receipt was associated with failure to screen, and thus, programs should include education on the necessity of screening as recommended by medical guidelines.https://www.mdpi.com/1718-7729/32/1/20hepatitis B virushepatitis B viral reactivationgastrointestinal cancercolorectal cancerscreening |
| spellingShingle | Jennifer Leigh Ranjeeta Mallick Stephanie Brule Lisa Rambout Jennifer Newton Dominick Bossé Curtis Cooper Joanna Gotfrit Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy Current Oncology hepatitis B virus hepatitis B viral reactivation gastrointestinal cancer colorectal cancer screening |
| title | Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy |
| title_full | Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy |
| title_fullStr | Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy |
| title_full_unstemmed | Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy |
| title_short | Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy |
| title_sort | implementation of a hepatitis b screening program in patients receiving systemic anti cancer therapy |
| topic | hepatitis B virus hepatitis B viral reactivation gastrointestinal cancer colorectal cancer screening |
| url | https://www.mdpi.com/1718-7729/32/1/20 |
| work_keys_str_mv | AT jenniferleigh implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy AT ranjeetamallick implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy AT stephaniebrule implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy AT lisarambout implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy AT jennifernewton implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy AT dominickbosse implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy AT curtiscooper implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy AT joannagotfrit implementationofahepatitisbscreeningprograminpatientsreceivingsystemicanticancertherapy |